Gilead Sciences (GILD) and Novo Nordisk A/S (NVO) announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis, or NASH. The intended clinical trial will be a proof of concept study combining Novo Nordisk’s semaglutide and Gilead’s cilofexo and firsocostat for the treatment of patients with NASH. The companies are also exploring the potential to collaborate on preclinical research to advance understanding of the disease.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.